Skip to main navigation
Company Logo
  • About
    • About Overview
    • Leadership
    • Careers
  • Product
    • RECELL® System
  • Clinical Development
    • Pipeline/Clinical Trials
    • Patient Outcomes
    • Proof Assets
  • News & Media
  • Investor Relations
    • Overview
    • Press Releases
    • Events & Presentations
    • Financials
    • Annual Reports & Proxy
    • Stock Information
    • Corporate Governance
    • FAQ
    • Email Alerts
    • Contact
  • Contact
  • Search
  • Overview
  • Press Releases
  • Events & Presentations
  • Financials
  • Annual Reports & Proxy
  • Stock Information
  • Corporate Governance
  • FAQ
  • Email Alerts
  • Contact
/press-releases/news-releases
global

Investors: Press Releases

AVITA Medical Announces Positive PermeaDerm® Study Results Demonstrating 70% Economic Advantage over Allograft and Comparable Clinical Outcomes
August 18, 2026
Learn More
AVITA Medical to Host Investor Webinar Briefing
August 9, 2026
Learn More
AVITA Medical Announces Participation at Canaccord Genuity Growth Conference
August 7, 2026
Learn More
  • News Releases
  • Announcements
August 18, 2026
AVITA Medical Announces Positive PermeaDerm® Study Results Demonstrating 70% Economic Advantage over Allograft and Comparable Clinical Outcomes
August 9, 2026
AVITA Medical to Host Investor Webinar Briefing
August 7, 2026
AVITA Medical Announces Participation at Canaccord Genuity Growth Conference
August 6, 2026
AVITA Medical Reports Second Quarter Results, Raises 2026 Revenue Guidance, and Expects Fourth Quarter Cash Flow Breakeven
July 14, 2026
AVITA Medical to Announce Second Quarter 2026 Financial Results
June 18, 2026
AVITA Medical Highlights First U.K. Clinical Experience with RECELL GO at British Burn Association Annual Meeting
May 17, 2026
AVITA Medical to Host Investor Webinar Briefing
May 14, 2026
AVITA Medical Reports First Quarter 2026 Financial Results
April 30, 2026
AVITA Medical Names Cary Vance as Chief Executive Officer
April 29, 2026
AVITA Medical Announces TGA Certification in Australia and Medsafe WAND Listing in New Zealand for RECELL GO
April 23, 2026
AVITA Medical to Announce First Quarter 2026 Financial Results
April 15, 2026
AVITA Medical Founder Fiona Wood Honored with Lifetime Achievement Award by American Burn Association
April 14, 2026
AVITA Medical Announces Positive Interim Results from Cohealyx® Study Demonstrating Accelerated Time to Skin Grafting
April 8, 2026
AVITA Medical Secures 10-Year BARDA Agreement Worth Up to $25.5M to Bolster U.S. Burn Emergency Preparedness
April 7, 2026
AVITA Medical Showcases Acute Burn and Wound Care Portfolio at ABA 2026, Featuring New Cohealyx Data
February 23, 2026
AVITA Medical to participate at the TD Cowen 46th Annual Health Care Conference
February 13, 2026
AVITA Medical to Host Investor Webinar Briefing
February 12, 2026
AVITA Medical Reports Fourth Quarter and Full Year 2025 Financial Results
January 25, 2026
Data at 2026 Boswick Burn & Wound Symposium highlight first integrated use of AVITA Medical technologies
January 13, 2026
AVITA Medical: Pre-J.P. Morgan Update Highlights 2025 Revenue Growth, New Debt Facility, and 2026 Growth Outlook
Pagination
  • Current page 1
  • Page 2
  • Next page ›
  • Last page »
AVITA Medical, Inc. Logo with tag

Contact Investor Relations

Ben Atkins
VP, Investor Relations and Corporate Communications
investor@avitamedical.com

Request Email Alerts

® 2026 AVITA Medical, Inc.
  • Terms of Use
  • Privacy Policy
  • CA Compliance
  • Social Media
  • CCPA
  • Compliance and Ethics
  • Important Safety Information

Social Media

  • Twitter (opens in new window)
  • Linkedin (opens in new window)